Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMD-OPTION
2023-508541-41-00Phase 2Completed
- Sponsor
- OMEICOS Therapeutics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, single-arm trial of OMT-28 in Mitochondriopathy, myopathies and Cardiomyopathies, sponsored by OMEICOS Therapeutics. Primary endpoint: Responder rate based on GDF-15 reduction. Started Dec 2023; status: completed.
02
Drugs
OMT-28
03
Conditions
MitochondriopathymyopathiesCardiomyopathies
Beyond the preview
Go deeper on 2023-508541-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508541-41-00.